Two Sigma Advisers’s Nektar Therapeutics NKTR Stock Holding History

Two Sigma Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-308,414	Closed	-$13M	–	1405
2025 Q4	$13M	Buy	308,414 +129,506	+72%	+$7.25M	0.03%	462
2025 Q3	$10.2M	Buy	+178,908	New	+$5.92M	0.02%	493
2025 Q2	–	Sell	-94,703	Closed	-$966K	–	2461
2025 Q1	$966K	Sell	94,703 -4,380	-4%	-$57.2K	﹤0.01%	1486
2024 Q4	$1.38M	Sell	99,083 -933	-0.9%	-$16.5K	﹤0.01%	1304
2024 Q3	$1.95M	Sell	100,016 -22,367	-18%	-$426K	﹤0.01%	1079
2024 Q2	$2.28M	Sell	122,383 -26,973	-18%	-$568K	0.01%	1118
2024 Q1	$2.09M	Sell	149,356 -55,280	-27%	-$579K	﹤0.01%	1200
2023 Q4	$1.73M	Sell	204,636 -45,327	-18%	-$343K	﹤0.01%	1370
2023 Q3	$2.23M	Sell	249,963 -3,606	-1%	-$34.7K	0.01%	1127
2023 Q2	$2.19M	Buy	253,569 +83,946	+49%	+$895K	0.01%	1149
2023 Q1	$1.79M	Buy	169,623 +134,047	+377%	+$4.06M	﹤0.01%	1329
2022 Q4	$1.21M	Sell	35,576 -6,667	-16%	-$323K	﹤0.01%	1486
2022 Q3	$2.03M	Buy	42,243 +31,274	+285%	+$1.86M	0.01%	1164
2022 Q2	$625K	Buy	10,969 +66	+0.6%	+$4.16K	﹤0.01%	1824
2022 Q1	$881K	Sell	10,903 -3,366	-24%	-$498K	﹤0.01%	1697
2021 Q4	$2.89M	Buy	14,269 +11,493	+414%	+$2.49M	0.01%	1011
2021 Q3	$748K	Buy	2,776 +1,533	+123%	+$369K	﹤0.01%	1746
2021 Q2	$320K	Sell	1,243 -313	-20%	-$86.6K	﹤0.01%	2115
2021 Q1	$467K	Buy	1,556 +187	+14%	+$58.2K	﹤0.01%	2041
2020 Q4	$349K	Sell	1,369 -1,660	-55%	-$429K	﹤0.01%	1996
2020 Q3	$754K	Buy	3,029 +2,253	+290%	+$709K	﹤0.01%	1627
2020 Q2	$270K	Buy	+776	New	+$242K	﹤0.01%	2164
2020 Q1	–	Sell	-1,643	Closed	-$532K	–	2535
2019 Q4	$532K	Buy	+1,643	New	+$476K	﹤0.01%	1857
2019 Q1	–	Sell	-1,031	Closed	-$509K	–	2407
2018 Q4	$509K	Sell	1,031 -16,483	-94%	-$9.95M	﹤0.01%	1762
2018 Q3	$16M	Sell	17,514 -3,174	-15%	-$2.71M	0.04%	451
2018 Q2	$15.2M	Buy	+20,688	New	+$23.9M	0.04%	461
2018 Q1	–	Sell	-3,854	Closed	-$3.45M	–	2376
2017 Q4	$3.45M	Sell	3,854 -691	-15%	-$409K	0.01%	991
2017 Q3	$1.64M	Buy	4,545 +1,321	+41%	+$413K	﹤0.01%	1306
2017 Q2	$945K	Sell	3,224 -9,417	-74%	-$2.72M	﹤0.01%	1546
2017 Q1	$4.45M	Sell	12,641 -9,026	-42%	-$2.03M	0.01%	863
2016 Q4	$3.99M	Buy	21,667 +5,709	+36%	+$1.16M	0.02%	833
2016 Q3	$4.11M	Buy	+15,958	New	+$4.11M	0.02%	721
2016 Q1	–	Sell	-822	Closed	-$208K	–	2098
2015 Q4	$208K	Buy	+822	New	+$169K	﹤0.01%	1657
2015 Q1	–	Sell	-2,332	Closed	-$542K	–	2234
2014 Q4	$542K	Buy	+2,332	New	+$498K	﹤0.01%	1570

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Two Sigma Advisers's NKTR Position: Q1 2026 in Review

Two Sigma Advisers sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 308,414 shares — an estimated $13M sold.

Two Sigma Advisers first reported a position in NKTR in Q4 2014 and held it in 34 quarters. The position peaked at $16M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Two Sigma Advisers reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 308,414 Nektar Therapeutics shares in Q1 2026, an estimated $13M.
Two Sigma Advisers first reported a position in Nektar Therapeutics in Q4 2014 and held it in 34 quarters.
Two Sigma Advisers's Nektar Therapeutics position peaked at $16M in Q3 2018.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.